Answers are grounded in this paper and cite their sources.
Eimeria has shown great potential as a vaccine vector; however, insufficient immune response intensity remains a key bottleneck limiting its development. In this study, we optimised antigen selection by using EtSAG13, the E. tenella surface antigen highly expressed during the sporozoite stage, as an immune‑enhancing molecule. Preliminary studies revealed that EtSAG13 exhibits a secreted expression pattern. By evaluating the protective efficacy and immune‑response potential of recombinant proteins derived from different regions of EtSAG13, we determined that the immunodominant epitopes of EtSAG13 are located in its N‑terminal region. We then fused the model antigen (enhanced yellow fluorescent protein, EYFP) to the N‑terminus of EtSAG13 to generate a transgenic Eimeria strain, EtSAG13-EYFP. Immunisation experiments demonstrated that, compared with the EtER strain expressing the model antigen alone, EtSAG13‑EYFP significantly enhanced both specific humoral and cellular immune responses against the model antigen. These results indicate that fusing a heterologous antigen with a dominant vector antigen improves the immunogenicity of the model antigen, providing data to support enhanced protective efficacy of transgenic Eimeria expressing foreign antigens. This strategy provides new insights into optimising the immunological efficacy of Eimeria as a vaccine vector, thereby enhancing its application potential for vector vaccine development.
No takes yet. Share an insight, caveat, or question.
Liao et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: